126 related articles for article (PubMed ID: 24742853)
1. Brimonidine effective but may lead to significant rebound erythema.
Ilkovitch D; Pomerantz RG
J Am Acad Dermatol; 2014 May; 70(5):e109-10. PubMed ID: 24742853
[No Abstract] [Full Text] [Related]
2. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine for erythema caused by rosacea.
Drug Ther Bull; 2014 Dec; 52(12):138-40. PubMed ID: 25505014
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine gel (Mirvaso) for rosacea.
Med Lett Drugs Ther; 2013 Oct; 55(1427):82-3. PubMed ID: 24129112
[No Abstract] [Full Text] [Related]
5. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
6. [Erythema of rosacea: a new and effective treatment].
Hougeir FG
Ann Dermatol Venereol; 2014 Sep; 141 Suppl 2():S169-74. PubMed ID: 25151933
[TBL] [Abstract][Full Text] [Related]
7. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
Routt ET; Levitt JO
J Am Acad Dermatol; 2014 Feb; 70(2):e37-8. PubMed ID: 24438976
[No Abstract] [Full Text] [Related]
8. MIRVASO (brimonidine tartrate) topical gel 0.33%.
Abramovits W; Prato A; Vincent KD; Scheinfeld N; Gupta AK
Skinmed; 2014; 12(1):41-3. PubMed ID: 24720083
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
10. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Del Rosso JQ
J Am Acad Dermatol; 2013 Dec; 69(6 Suppl 1):S44-56. PubMed ID: 24229637
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
[TBL] [Abstract][Full Text] [Related]
13. [Brimonidine (Mirvaso), dermal use].
Van Genechten D
J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
[No Abstract] [Full Text] [Related]
14. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
Oon HH; Lim ZV
Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
[TBL] [Abstract][Full Text] [Related]
15. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Del Rosso JQ; Thiboutot D; Gallo R; Webster G; Tanghetti E; Eichenfield LF; Stein-Gold L; Berson D; Zaenglein A;
Cutis; 2014 Mar; 93(3):134-8. PubMed ID: 24738094
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
Kaneko E; Wada T; Minagawa Y; Inoue Y
Nihon Yakurigaku Zasshi; 2012 Oct; 140(4):177-82. PubMed ID: 23059902
[No Abstract] [Full Text] [Related]
17. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
18. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
19. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.
Werner K; Kobayashi TT
Dermatol Online J; 2015 Jan; 21(3):. PubMed ID: 25780983
[TBL] [Abstract][Full Text] [Related]
20. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
